Agilent Technologies, Inc. $A Shares Bought by BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp

BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp grew its holdings in shares of Agilent Technologies, Inc. (NYSE:A) by 9.5% in the first quarter, according to its most recent filing with the SEC. The firm owned 362,019 shares of the medical research company’s stock after acquiring an additional 31,299 shares during the quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp’s holdings in Agilent Technologies were worth $42,349,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. boosted its position in Agilent Technologies by 13.5% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 36,674 shares of the medical research company’s stock worth $4,279,000 after acquiring an additional 4,362 shares during the period. Assenagon Asset Management S.A. raised its stake in shares of Agilent Technologies by 8.3% in the 1st quarter. Assenagon Asset Management S.A. now owns 30,827 shares of the medical research company’s stock worth $3,606,000 after buying an additional 2,371 shares in the last quarter. Alps Advisors Inc. raised its stake in shares of Agilent Technologies by 29.5% in the 1st quarter. Alps Advisors Inc. now owns 13,358 shares of the medical research company’s stock worth $1,563,000 after buying an additional 3,040 shares in the last quarter. D.A. Davidson & CO. raised its stake in shares of Agilent Technologies by 30.4% in the 1st quarter. D.A. Davidson & CO. now owns 9,474 shares of the medical research company’s stock worth $1,108,000 after buying an additional 2,207 shares in the last quarter. Finally, LGT Capital Partners LTD. raised its stake in shares of Agilent Technologies by 7.6% in the 1st quarter. LGT Capital Partners LTD. now owns 768,252 shares of the medical research company’s stock worth $89,870,000 after buying an additional 54,302 shares in the last quarter. Institutional investors and hedge funds own 87.41% of the company’s stock.

Agilent Technologies Stock Up 3.7%

NYSE:A opened at $121.4920 on Friday. The firm has a market capitalization of $34.51 billion, a price-to-earnings ratio of 30.00, a PEG ratio of 3.55 and a beta of 1.22. Agilent Technologies, Inc. has a 1-year low of $96.43 and a 1-year high of $153.84. The company has a current ratio of 2.09, a quick ratio of 1.60 and a debt-to-equity ratio of 0.55. The business’s fifty day moving average price is $117.88 and its 200 day moving average price is $117.47.

Agilent Technologies (NYSE:A) last posted its quarterly earnings results on Wednesday, May 28th. The medical research company reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.26 by $0.05. The firm had revenue of $1.67 billion for the quarter, compared to analyst estimates of $1.63 billion. Agilent Technologies had a return on equity of 25.92% and a net margin of 17.59%.Agilent Technologies’s quarterly revenue was up 6.0% on a year-over-year basis. During the same period in the previous year, the firm earned $1.22 earnings per share. Agilent Technologies has set its FY 2025 guidance at 5.540-5.610 EPS. Q3 2025 guidance at 1.350-1.370 EPS. On average, sell-side analysts forecast that Agilent Technologies, Inc. will post 5.58 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A has been the topic of a number of research reports. Barclays boosted their price objective on Agilent Technologies from $115.00 to $125.00 and gave the stock an “equal weight” rating in a research note on Tuesday, June 24th. Evercore ISI boosted their price objective on Agilent Technologies from $125.00 to $130.00 and gave the stock an “in-line” rating in a research note on Tuesday, July 8th. TD Cowen boosted their price objective on Agilent Technologies to $150.00 and gave the stock a “buy” rating in a research note on Thursday, May 29th. UBS Group dropped their price objective on Agilent Technologies from $150.00 to $130.00 and set a “neutral” rating on the stock in a research note on Thursday, May 29th. Finally, JPMorgan Chase & Co. dropped their price objective on Agilent Technologies from $160.00 to $155.00 and set an “overweight” rating on the stock in a research note on Thursday, May 29th. Seven equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, Agilent Technologies has a consensus rating of “Moderate Buy” and an average price target of $139.77.

Insider Activity

In other news, CEO Padraig Mcdonnell sold 1,508 shares of the stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $117.44, for a total value of $177,099.52. Following the completion of the sale, the chief executive officer directly owned 37,448 shares of the company’s stock, valued at $4,397,893.12. This represents a 3.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.26% of the stock is owned by company insiders.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.